high-risk patients with febrile neutropenia
Conditions
Interventions
Group1:Biapenem 0.3g q6h
Group2:Biapenem 0.3g q8h
Group3:Biapenem 0.6g q6h
Group4:Biapenem 0.6g q8h
Sponsors
The Affilated Hospital of Putian University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Greater than 18 years old, male or female; 2. High-risk patients with febrile neutropenia(Diagnostic criteria refer to the 2010 edition of the treatment guidelines for IDSA); 3. Medication standard is in line with The National Health Commission of the People's Republic of China 's Consensus of Clinical Experts on Using Carbapenem Antibiotics; 4. At least one steady-state plasma concentration can be obtained; 5. Patient and family informed consent.
Exclusion criteria
Exclusion criteria: 1. Pregnant women and lactating women; 2. Those who have a history of allergies to carbapenems, penicillins or other ß-lactam antibiotics; 3. Patients with a history of epilepsy or central nervous system disorders, patients with treating sodium valproate; 4. Patients infected by other pathogenic microorganisms such as viruses, fungi, tuberculosis, mycoplasma, chlamydia, rickettsia or Legionella; 5. Patients with severe liver and kidney dysfunction; 6. Patients who are unable to complete the trial under the study protocol or who are unlikely to complete the expected course of treatment and follow-up and patients with poor compliance.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood Concentration of biapenem;temperature;leukocyte;Neutrophil;C-Reactive Protein;Procalcitonin;Clinical symptoms; | — |
Secondary
| Measure | Time frame |
|---|---|
| Age;Gender;Weight; | — |
Countries
China
Contacts
Public ContactZhang Chaofeng
The Affilated Hospital of Putian University
Outcome results
None listed